Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 3, 2025 • 7:01 PM ET

Date/Time Source News Release
04/01/2025 04:49 PM EDT GlobeNewswire BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
03/31/2025 07:00 AM EDT GlobeNewswire BioStem Announces Notice of Allowance for Two U.S. Patent Applications
03/27/2025 07:00 AM EDT GlobeNewswire BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
02/24/2025 07:00 AM EST GlobeNewswire BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
01/13/2025 07:00 AM EST GlobeNewswire BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
01/08/2025 07:00 AM EST GlobeNewswire BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
01/02/2025 07:00 AM EST GlobeNewswire BioStem Technologies CEO to Present at Biotech Showcase 2025
11/25/2024 07:00 AM EST GlobeNewswire BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
11/20/2024 07:00 AM EST GlobeNewswire BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
11/12/2024 07:29 AM EST GlobeNewswire BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
Page

Additional News

As of April 3, 2025 • 7:01 PM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.